Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Observer-blind, Active Comparator-controlled, Multicenter, Phase 3 Study to Assess the Efficacy, Safety, and Immunogenicity of a Plant-derived Quadrivalent VLP Influenza Vaccine in Adults 65 Years of Age and Older

Next Previous
Trial Profile

A Randomized, Observer-blind, Active Comparator-controlled, Multicenter, Phase 3 Study to Assess the Efficacy, Safety, and Immunogenicity of a Plant-derived Quadrivalent VLP Influenza Vaccine in Adults 65 Years of Age and Older

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 29 Dec 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs MT-2271 (Primary) ; GSK 2321138A
  • Indications Influenza virus infections
  • Focus Registrational; Therapeutic Use
  • Sponsors Medicago

Most Recent Events

  • 31 Oct 2025 According to a Tanabe Pharma Corporation media release, Mitsubishi Tanabe Pharma Corporation is now called Tanabe Pharma Corporation.
  • 13 Oct 2020 Results assessing efficacy, immunogenicity, and safety of a plant-derived, quadrivalent, virus like particle influenza vaccine published in the THE LANCET
  • 28 Apr 2020 Primary endpoint has been met. (Occurrence of protocol-defined Influenza-Like Illnesses (ILI) cause by any influenza viral type/subtype)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top